
usd jan pm et
summari compani manufactur scientif analyt equip liquid chromatographi
thermal analysi mass spectrometri product
nm price-to-earnings oper ep
liquid chromatographi mass spectrometri
market off-set highli competit marketplac
depend unpredict pharmaceut
budget approxim sale pharma
custom produc volatil sale swing life
scienc tool maker pharma budget
unexpectedli face larg cut unanticip drug patent
challeng pipelin failur reduc sale forecast
fiscal year end dec ep estim base cfra
oper earn histor earn report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
oct pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
corpor rais
target
ep estim slightli
five-year averag forward price-to-earnings expect
growth moder year ahead ep
vs ahead
estim rais ep estim
revenu growth yoy driven
acceler -- yoy
vs china sale growth
continu impress well around
yoy cy revenu growth slow
howev expect modest
deceler around despit
improv oper margin
lower sg expect
improv year back robust
 growth continu
buyback support ep growth near
given slow sale
growth feel less premium valuat
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview corp manufactur distribut servic analyt instrument
pharmaceut life scienc biochem industri academ govern end-market analyt
instrument compon manufactur includ high-perform liquid chromatographi hplc
instrument ultra perform liquid chromatographi uplc column consum mass
spectrometri ms instrument integr analyt instrument thermal
analysi ta rheolog instrument liquid chromatographi standard techniqu identifi
analyz constitu compon variou chemic materi uniqu perform capabl
let separ identifi known chemic materi hplc uplc use analyz
substanc varieti industri qualiti control process engin applic
life scienc industri use hplc uplc primarili identifi new drug
uplc provid comprehens chemic separ faster analysi time compar hplc
ms analyt techniqu use identifi unknown compound quantifi known materi
elucid structur chemic properti molecul measur mass individu
molecul convert ion product serv divers market includ
pharmaceut environment industri
divis make servic thermal analysi rheolog instrument use
physic character polym relat materi thermal analysi measur physic
characterist materi function temperatur chang temperatur affect sever
characterist materi physic state weight dimens mechan electr
properti may measur use thermal analysi techniqu result thermal analysi
wide use develop produc character materi industri plastic chemic
compani introduc acquiti uplc m-class instrument system system deliv
sensit quantifi identifi vanishingli small concentr key molecul particularli
use mass spectrometr detect innov incorpor acquiti uplc m-class
system led intern low-volum design newli redesign fluidic minim dispers
adsorpt loss chromatograph separ compani introduc acquiti
arc system enabl arc multi-flow path technolog bridg gap hplc
uplc emul variou hplc system without alter method gradient tabl enabl
improv chromatograph perform method
market profil market three analyt instrument compet estim
billion billion compani world largest maker chromatographi instrument
chromatographi column relat consum largest market share europ
non-japan asia lead posit japan hplc largest product segment analyt
instrument market uplc instrument gain market share also believ maintain
lead market share mass spectrometri marketplac accord trade public instrument
busi outlook third largest market share estim
competit landscap analyt instrument system market highli competit
compani believ compet primarili basi perform reliabl servic
lesser extent price within hplc uplc ms market competitor includ publicli trade
compani shimadzu corpor
corpor howev believ compani offer compar product acquiti uplc
within thermal analysi market compani princip competitor includ
mettler-toledo intern shimadzu corpor malvern instrument
financi trend sale grown billion billion repres
three-year compound annual growth rate compound-annual-growth-rate adjust ep rose
repres three-year compound-annual-growth-rate repurchas billion common stock
april board author repurchas billion stock
compani anticip use billion repatri cash reduc debt repurchas common stock
senior vice presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc januari technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
lst sub-industri
next month think among
fastest-grow sub-industri within health
care sector driver earn growth
sub-industri next year
view strong growth public fund
health care research increas
spend biopharmaceut compani
budget nation institut
nih grew rapidli last three year
materi increas fund academ
govern lab turn drive sale
growth lst compani gener
materi portion revenu lab
fy nih budget grew
fy
budget increas aid lst
sub-industri sale growth
forecast
expect anoth materi nih budget
increas fy support robust
demand sub-industri product
year ahead well
addit public-fund health care
research expect larg increas privat
biopharmaceut spend drive sale
growth life scienc tool servic
sub-industri month end septemb
estim spend
increas year-over-year
spend biotech
depart research tool product
well contract research servic
 growth continu year ahead
translat continu solid sale growth
lst sub-industri
care research type prolifer
around world particularli china
emerg market turn
drive strong intern sale growth
establish life scienc tool servic
compani china particular
view howev tailwind may moder
china face slowdown econom
growth use five largest compani
lst sub-industri proxi estim
averag growth sub-industri
china-deriv sale slow
year-over-year
long-term though think china
major emerg market nation like india
need continu rapidli increas health care
expenditur parallel grow
middl class turn like continu
support strong sale growth lst
sub-industri see happen despit
potenti neg impact
import/export tariff limit
large-scal supplier option
state-of-the-art lst product outsid
compani notabl except
switzerland-bas roch
 life
rise
 life
drop
base index
five-year market price perform jan
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
corpor rais target
slightli peer ep estim set
ep vs ahead estim sale aid fx
benefit rose broad-bas growth across product geographi sale
pharmaceut end-market rose aid double-digit growth china
rebound india industri market rose sale
govern market rose though note market volatil guid
sale growth mid-singl digit ep /jeffrey loo cfa
et cfra keep buy opinion share corpor
rais target in-lin
peer forward ep estim rais
ep estim ep
vs ahead estim sale fx benefit rose
broad-bas growth across end-market pharma sale rose
industri government/academ rose see continu
benefit rise global regulatori standard along increas use mass
spectrometri routin workflow process includ food safeti /jeffrey loo
et cfra keep buy opinion share corpor
rais target in-lin
peer forward ep estim ep vs
ahead estim lift estim
sale rose pharmaceut
end-market moder growth high singl digit industri
solid growth govern improv growth prior
geograph sale asia rose europ sale america
fell sale see improv /jeffrey loo
analyst research note compani news
rais target
ep estim slightli five-year averag forward price-to-earnings
expect growth moder year ahead ep vs
ahead estim rais ep estim
revenu growth yoy driven acceler
-- yoy vs china sale growth
continu impress well around yoy cy revenu growth
slow howev expect
modest deceler around despit modest sale
slowdown materi improv oper margin
lower sg expect improv year back robust
 growth continu buyback support ep growth near
given slow sale growth feel less premium
valuat warrant /colin scarola
hold buy lower target
ep estim line five-year averag forward price-to-earnings
ep vs line estim lower ep
estim initi
concern loss sale growth momentum sale growth
fell yoy averag prior four quarter sale
pharmaceut custom total led slowdown yoy growth
versu averag prior four quarter despit slower top-lin
growth still grew adjust ep yoy aid estim bp
improv ebita margin yet buyback drove half ep
gain would like see actual earn growth drive lion share
ep gain expect continu buyback support ep growth
high singl digit given slow revenu growth feel premium
valuat less warrant /colin scarola
et cfra keep buy opinion share corpor
keep target slightli peer
forward ep estim see continu sale
momentum ep vs estim keep
ep estim rais ep estim sale
fx benefit rose repres sequenti improv
sale softer expect particularli india mass
spectrometri line sale mass spectrometri improv driven solid
growth core tandem quadrupol product note
high-resolut mass spectrometri line continu affect soft
biomed research sale india flat anticip improv
expect purchas pattern normal advers
impact chang countri good servic tax sale china
grew mid-teen thermal analysi unit grew aid new
et cfra keep buy opinion share corpor
keep target slightli peer
ep estim lead market share
ep vs ahead view sale aid
fx benefit rose strong sale pharmaceut govern end
market respect sale ta product line rose
constant currenc basi instrument sale fell recur sale
rose sale india mass spectrometri product line weaker
expect due soft biomed research believ
temporari along chang within sale team complet
expect sale improv mass spectrometri throughout year sale
india advers impact chang good servic tax gst
expect normal board approv new stock
buy-back program addit remain prior buy-back
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
